TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07496567: A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related

Sponsor: EyeBiotech Ltd. · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 960 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,126,000

Rescue Site Savings

+$6,683,160

Unlock Full NCT07496567 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07496567 Rescue Dossier →